AstraZeneca Plc (AZN)

43.87
0.26 0.59
NYSE : Health Technology
Prev Close 44.13
Open 44.18
Day Low/High 43.67 / 44.20
52 Wk Low/High 35.30 / 46.22
Volume 1.65M
Avg Volume 3.45M
Exchange NYSE
Shares Outstanding 2.62B
Market Cap 114.91B
EPS 0.80
P/E Ratio 19.79
Div & Yield 1.37 (3.10%)

Latest News

AstraZeneca Launches Signature STEM Program To Empower Students To Live Healthier Lives And Inspire Future Scientists

AstraZeneca Launches Signature STEM Program To Empower Students To Live Healthier Lives And Inspire Future Scientists

AstraZeneca today announced the launch of a new STEM — science, technology, engineering, and mathematics — program in partnership with Learning Undefeated and Discovery Education, with the mutual goals of inspiring the next generation about science and...

FASENRA® (benralizumab) Approved In The US For Self-administration In A New Pre-filled Auto-injector, The FASENRA Pen™

FASENRA® (benralizumab) Approved In The US For Self-administration In A New Pre-filled Auto-injector, The FASENRA Pen™

AstraZeneca today announced that the US Food and Drug Administration (FDA) has approved the self-administration of FASENRA ® (benralizumab) in a pre-filled, single-use auto-injector (the FASENRA Pen™).

TAGRISSO Is The Only 1st-line Treatment For EGFR-Mutated Non-Small Cell Lung Cancer To Deliver A Median Overall Survival Of More Than Three Years

TAGRISSO Is The Only 1st-line Treatment For EGFR-Mutated Non-Small Cell Lung Cancer To Deliver A Median Overall Survival Of More Than Three Years

AstraZeneca today presented detailed overall survival (OS) results from the Phase III FLAURA trial of TAGRISSO® (osimertinib) in the 1st-line treatment of adult patients with locally-advanced or metastatic epidermal growth factor receptor (EGFR)-mutated...

BRILINTA Monotherapy In High-Bleeding Risk Patients Who Underwent PCI Had Reduced Risk Of Clinically Relevant Bleeding Than With Dual Antiplatelet Therapy In The TWILIGHT Trial

BRILINTA Monotherapy In High-Bleeding Risk Patients Who Underwent PCI Had Reduced Risk Of Clinically Relevant Bleeding Than With Dual Antiplatelet Therapy In The TWILIGHT Trial

New data from TWILIGHT, a Phase IV independent trial (funded by AstraZeneca), showed that in patients at high-bleeding risk who underwent PCI and completed three months of dual antiplatelet therapy, BRILINTA (ticagrelor) monotherapy (90 mg twice daily)...

FDA Grants Fast Track Designation For FARXIGA In Heart Failure

FDA Grants Fast Track Designation For FARXIGA In Heart Failure

AstraZeneca today announced that the US Food and Drug Administration (FDA) has granted Fast Track designation for the development of FARXIGA (dapagliflozin) to reduce the risk of cardiovascular (CV) death or the worsening of heart failure in adults with...

IMFINZI Is First Immunotherapy To Show Both Significant Survival Benefit And Improved, Durable Responses In Extensive-Stage Small Cell Lung Cancer

IMFINZI Is First Immunotherapy To Show Both Significant Survival Benefit And Improved, Durable Responses In Extensive-Stage Small Cell Lung Cancer

AstraZeneca today presented detailed results from the Phase III CASPIAN trial, showing IMFINZI ® (durvalumab) significantly improved overall survival (OS) in patients with previously-untreated extensive-stage small cell lung cancer (SCLC).

BRILINTA Reduced The Risk Of Cardiovascular Events In Patients With Coronary Artery Disease And Type 2 Diabetes In Phase III THEMIS Trial

BRILINTA Reduced The Risk Of Cardiovascular Events In Patients With Coronary Artery Disease And Type 2 Diabetes In Phase III THEMIS Trial

AstraZeneca today announced detailed results from the positive Phase III THEMIS trial, which showed BRILINTA (ticagrelor) plus aspirin reduced the relative risk for the composite of cardiovascular (CV) death, heart attack, or stroke by 10% (7.

Detailed Results From Phase III DAPA-HF Trial Showed FARXIGA Significantly Reduced Both The Incidence Of Cardiovascular Death And The Worsening Of Heart Failure

Detailed Results From Phase III DAPA-HF Trial Showed FARXIGA Significantly Reduced Both The Incidence Of Cardiovascular Death And The Worsening Of Heart Failure

AstraZeneca today announced detailed results from the landmark Phase III DAPA-HF trial that showed FARXIGA (dapagliflozin) on top of standard of care reduced both the incidence of cardiovascular (CV) death and the worsening of heart failure.

PT010 Phase III ETHOS Trial Met Its Primary Endpoint In Chronic Obstructive Pulmonary Disease

PT010 Phase III ETHOS Trial Met Its Primary Endpoint In Chronic Obstructive Pulmonary Disease

AstraZeneca today announced positive results from the Phase III ETHOS trial for triple-combination therapy PT010 in patients with moderate to very severe chronic obstructive pulmonary disease (COPD).

FDA Grants Fast Track Designation For FARXIGA In Chronic Kidney Disease

FDA Grants Fast Track Designation For FARXIGA In Chronic Kidney Disease

AstraZeneca today announced that the US Food and Drug Administration (FDA) has granted Fast Track designation for the development of FARXIGA (dapagliflozin) to delay the progression of renal failure and prevent cardiovascular (CV) and renal death in...

Amgen Adds Celgene's Otezla to Bolster Pipeline at Pricey Valuation

Amgen Adds Celgene's Otezla to Bolster Pipeline at Pricey Valuation

Amgen is finally making an expected splash out of its cash pile, but questions are abounding about the cost paid for Celgene's Otezla.

Moderna Stock Surges as FDA Fast Tracks Zika Vaccine

Moderna Stock Surges as FDA Fast Tracks Zika Vaccine

The biotech's investigational Zika vaccine is being evaluated in a Phase I study.

FARXIGA Met Primary Endpoint In Landmark Phase III DAPA-HF Trial For The Treatment Of Patients With Heart Failure

FARXIGA Met Primary Endpoint In Landmark Phase III DAPA-HF Trial For The Treatment Of Patients With Heart Failure

AstraZeneca today announced positive results from the landmark Phase III DAPA-HF trial which showed that FARXIGA (dapagliflozin) met the primary composite endpoint with a statistically-significant and clinically-meaningful reduction of cardiovascular...

5 Favorites for Biotech Stock Buyers

5 Favorites for Biotech Stock Buyers

For those with a long-term horizon, here are some top picks.

CALQUENCE® (acalabrutinib) Granted US Breakthrough Therapy Designation For Chronic Lymphocytic Leukemia

CALQUENCE® (acalabrutinib) Granted US Breakthrough Therapy Designation For Chronic Lymphocytic Leukemia

AstraZeneca today announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) for CALQUENCE ® (acalabrutinib) as a monotherapy treatment for adult patients with chronic lymphocytic leukemia (CLL), one of the...

TAGRISSO® (OSIMERTINIB) Significantly Improves Overall Survival In The Phase III FLAURA Trial For 1st-line EGFR-mutated Non-small Cell Lung Cancer

TAGRISSO® (OSIMERTINIB) Significantly Improves Overall Survival In The Phase III FLAURA Trial For 1st-line EGFR-mutated Non-small Cell Lung Cancer

AstraZeneca today announced positive overall survival (OS) results from the Phase III FLAURA trial, a randomized, double-blinded, multicenter trial of TAGRISSO in previously-untreated patients with locally-advanced or metastatic non-small cell lung cancer...

LYNPARZA® (Olaparib) Phase III Profound Trial In HRR* Mutation-Selected Metastatic Castration-Resistant Prostate Cancer Met Primary Endpoint

LYNPARZA® (Olaparib) Phase III Profound Trial In HRR* Mutation-Selected Metastatic Castration-Resistant Prostate Cancer Met Primary Endpoint

AstraZeneca and Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced positive results from the Phase III PROfound trial of LYNPARZA 300 mg (two 150 mg tablets) twice daily in men with metastatic castration-resistant...

Big Pharma Sees Pockets of Recent Insider Buying

Big Pharma Sees Pockets of Recent Insider Buying

AbbVie and Bristol-Myers Squibb are two pharmaceutical giants where insiders have snatched up big blocks of stock.

Mylan Jumps on Deal With Pfizer to Form New Company

Mylan Jumps on Deal With Pfizer to Form New Company

Pfizer will combine its off-patent drug business with Mylan in the as-yet-to-be-named new company.

3 Trends Driving This Earnings Season

3 Trends Driving This Earnings Season

With a third of S&P 500 stocks having reported, these 3 trends are coming to the fore.

IMFINZI® (durvalumab) US Label Updated With Overall Survival Data In Unresectable, Stage III Non-small Cell Lung Cancer

IMFINZI® (durvalumab) US Label Updated With Overall Survival Data In Unresectable, Stage III Non-small Cell Lung Cancer

AstraZeneca today announced that the US Food and Drug Administration (FDA) has approved the inclusion of overall survival (OS) data from the Phase III PACIFIC trial in an update to the IMFINZI ® (durvalumab) US Prescribing Information for patients with...

AstraZeneca Outlines Drug Pipeline, Partnerships, Pricing Impacts

AstraZeneca Outlines Drug Pipeline, Partnerships, Pricing Impacts

Here's what you need to know if AstraZeneca's pipeline could affect your portfolio.

AstraZeneca Biopharma President Talks Drug Rebates, Pricing

AstraZeneca Biopharma President Talks Drug Rebates, Pricing

Is pharma feeling the pressure now that PBM stocks are released from regulatory risk?

IMFINZI® (durvalumab) Improves Overall Survival At Interim Analysis In The Phase III CASPIAN Trial In 1st-Line Extensive-Stage Small Cell Lung Cancer

IMFINZI® (durvalumab) Improves Overall Survival At Interim Analysis In The Phase III CASPIAN Trial In 1st-Line Extensive-Stage Small Cell Lung Cancer

AstraZeneca today announced positive overall survival (OS) results from the Phase III CASPIAN trial with IMFINZI in 1st-line extensive-stage small cell lung cancer (SCLC), a disease with significant unmet need and limited treatment options for patients.

CALQUENCE® (acalabrutinib) Significantly Prolonged The Time Patients Lived Without Disease Progression In Relapsed Or Refractory Chronic Lymphocytic Leukemia

CALQUENCE® (acalabrutinib) Significantly Prolonged The Time Patients Lived Without Disease Progression In Relapsed Or Refractory Chronic Lymphocytic Leukemia

AstraZeneca today announced detailed results from the interim analysis of the Phase III ASCEND trial at the European Hematology Association (EHA) Annual Congress in Amsterdam, showing CALQUENCE ® (acalabrutinib) significantly prolonged the time patients...

TheStreet Quant Rating: B (Buy)